Equities research analysts forecast that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will report sales of $77.74 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $80.30 million and the lowest estimate coming in at $72.88 million. Supernus Pharmaceuticals reported sales of $56.81 million during the same quarter last year, which would suggest a positive year over year growth rate of 36.8%. The business is scheduled to report its next quarterly earnings results on Friday, January 19th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year sales of $77.74 million for the current financial year, with estimates ranging from $290.99 million to $298.25 million. For the next year, analysts forecast that the firm will report sales of $387.71 million per share, with estimates ranging from $371.36 million to $416.37 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%.

Several research analysts recently issued reports on SUPN shares. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a report on Thursday, July 13th. Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 5th. Jefferies Group LLC increased their price target on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. BidaskClub cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $48.29.

Supernus Pharmaceuticals (SUPN) opened at 48.575 on Friday. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of 24.508 and a beta of 1.30. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $50.00. The firm’s 50 day moving average price is $44.15 and its 200-day moving average price is $37.39.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at $623,250. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the transaction, the vice president now directly owns 21,209 shares of the company’s stock, valued at $952,284.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 160,000 shares of company stock valued at $7,505,574. 6.70% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of SUPN. Meeder Asset Management Inc. increased its holdings in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in Supernus Pharmaceuticals in the first quarter valued at about $127,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 91.4% in the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares in the last quarter. Finally, Advisor Group Inc. increased its holdings in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares in the last quarter. 95.38% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Announce Quarterly Sales of $77.74 Million” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/zacks-analysts-anticipate-supernus-pharmaceuticals-inc-supn-will-announce-quarterly-sales-of-77-74-million.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.